Tested positive for Flu type A; Lack of efficacy; Started having symptoms which have progressed to moderate and occasionally severe; This spontaneous case initially received on 13-Jan-2025, was reported by a non health professional and concerns an adult female patient. No medical history was reported Concomitant medication: refer to appropriate report section. Administration of company suspect drug(s): On 28-Dec-2024, the patient received Flucelvax (TIV) for an unknown indication, dose regimen: not reported, route of administration and anatomical location: not reported, Lot number: No batch number available, and wont be requested due to no follow-up consent. No additional suspect drugs. Adverse reactions/events and outcomes: On 12-Jan-2025, 15 days after vaccination, the patient experienced Lack of efficacy (Medically Significant, outcome: Not Reported). On 12-Jan-2025, 15 days after vaccination, the patient experienced Tested positive for Flu type A (Medically Significant, outcome: Unknown). Associated symptoms included: Started having symptoms which have progressed to moderate and occasionally severe. Patient received the Flucelvax vaccine on 28-Dec-2024 at a pharmacy. On 12-Jan-2025, she tested positive for Flu type A, started having symptoms on 10-Jan-2025 which had progressed to moderate and occasionally severe. Quality assurance informed that this is not a PTC just an adverse event. Flucelvax (TIV) action taken: Not Applicable Reporter assessment: the reporter did not provide a seriousness and causality assessment for the events.; Reporter’s Comments: Causality: Related for influenza and drug ineffective. Due to the spontaneous nature of the case, it is considered related for reporting purposes. However, the onset of protective effects of vaccination is usually 21 days post vaccination. This case is not considered an unusual failure of efficacy.